Glenmark Pharmaceuticals Ltd said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd for commercialising its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.

• Dhoot Transmission Hits 52-Week High, Stock Up 70% From IPO
• Premier Energies Order Book Swells to Rs 15,000 Cr
• Strides Pharma Shares Jump 10% on USFDA Bengaluru Clearance
• Trump Set to Cut Canada Auto Tariffs to 15% in Proposed Trade Deal
• L&T Shares Rise After Winning Rs 5,000 Crore Dubai Airport Order

Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lotus Pharmaceutical Co, Ltd (Lotus), Glenmark will be responsible for the manufacturing and supply of Ryaltris.

On the other hand Lotus will be responsible for its commercialization subject to receipt of regulatory approvals, in these markets, the company said in a statement.